Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better.

Abstract	Atypical hemolytic uremic syndrome (HUS) secondary to anti-factor H autoantibodies has a poor prognosis. The study by Sinha et al. of a large cohort of Indian children makes a substantial contribution to improved management of this form of HUS by showing that standardized titration of anti-factor H autoantibodies is applicable worldwide and that early treatment initiation and guidance of maintenance treatment by autoantibody titer monitoring significantly improve outcomes.
Authors	Chantal Loirat, Véronique Frémeaux-Bacchi
Journal	Kidney international (Kidney Int) Vol. 85 Issue 5 Pg. 1019-22 (May 2014) ISSN: 1523-1755 [Electronic] United States
PMID	24786877 (Publication Type: Journal Article, Comment)
Chemical References	Autoantibodies Blood Proteins CFHR1 protein, human CFHR3 protein, human Complement C3b Inactivator Proteins Immunosuppressive Agents
Topics	Autoantibodies (blood) Blood Proteins (immunology) Complement C3b Inactivator Proteins (immunology) Female Hemolytic-Uremic Syndrome (therapy) Humans Immunosuppressive Agents (therapeutic use) Male Plasma Exchange Time-to-Treatment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!